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 Introduction: Hyperuricemia is a cause and effect of chronic kidney 
disease (CKD), accelerates its progression and predisposes to acute 
kidney injury. Present study aimed to find out the outcome of Febuxostat 
treatment in hyperuricemic pre-dialysis CKD patients. 
Method: This was a cross sectional study conducted in Nephrology 
department, Bir hospital, Nepal, during from February 2019 to January 
2020, among pre-dialysis CKD stage 3-5 non dialysis (ND) patients with 
serum uric acid (SUA) >7 mg/d L who were treated with Febuxostat 40 
mg once a day and followed up at one, two and three months. The 
baseline SUA, creatinine, estimated glomerular filtration rate (eGFR) 
calculated by the modification of diet in renal disease (MDRD) equation 
compared with values at follow up and according to CKD stages. The 
adverse effects and liver enzymes were recorded. 
Result: There were total 50 patients, mean age 54.2±16.5 years, male 31 
(62%). There were significant reductions of SUA from baseline of 8.9±1.4 
to 7.1±1.2 vs 5.9±0.9 vs 4.7±1.0) at one, two and three month 
respectively, p=0.000 and increment of eGFR (ml/min/1.73m2) from 
29.6±15.0 to 31.6±16.0, 33.6±16.6, 34.1±17.1, p=0.000 and 41 (82%) 
patients achieved uric acid < 6mg/dl at three month. Significant 
reduction of uric acid in all CKD stages and increment of eGFR in CKD 
stage 3 and 4 were observed. Adverse effects were epigastralgia in 5 
(10%) and joint pain in 13 (26%). 
Conclusion: Febuxostat is an effective SUA lowering drug in pre-dialysis 
chronic kidney disease patients with improvement of kidney function. 
Keywords: hyperuricemia, chronic kidney disease (CKD), dialysis, 
Febuxostat, uric acid 
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Introduction 
 
Chronic Kidney disease (CKD) and 
hyperuricemia are interrelated. The CKD 
results in hyperuricemia due to decreased 
excretion of uric acid.1 Hyperuricemia results 
and accelerates the progression of CKD and 
acute kidney injury (AKI) by mechanisms 
beyond urate crystal deposition.2-4 
 
Hyperuricemia is defined as a serum uric acid 
(SUA) concentrations that exceeds the limit of 
solubility (7.0mg/dl).5 It is associated with 
greater incidence of end stage renal disease 
and increased risk of AKI.6,7 In CKD patients 
with hyperuricemia, allopurinol is effective in 
lowering SUA with stable kidney function.8 
However, Febuxostat is superior with 
significantly increased eGFR (estimated 
glomerular filtration rate) and longer renal 
survival time than allopurinol .9, 10 
 
With newer evidences, hyperuricemia in CKD 
is treated with Febuxostat in our department. 
So, present study aimed to find out the 
outcome of Febuxostat treatment in pre-
dialysis CKD patients and its effect on SUA and 





This was a cross sectional study carried out in 
Department of Nephrology, Bir Hospital from 
February 2019 to January 2020 after approval 
from Institutional Review Board (IRB), 
National Academy of Medical Sciences 
(NAMS), Kathmandu, Nepal. Established CKD 
patients with eGFR<60 ml/min/1.73 m2 (CKD 
stages 3 to 5, ND) and uric acid >7 mg/dl were 
included. The exclusion criteria were raised 
liver enzymes (ALT and AST greater than twice 
the upper limit of laboratory reference range), 
acute kidney injury, renal transplant recipient, 
CKD on dialysis, history of malignancy, 
hypersensitivity to Febuxostat, on drugs like 
azathioprine, mercaptopurine hydrate, 
allopurinol, vidarabin and didanosine, 
pregnant lady, lactating mother and planning 
for pregnancy during the study period. 
 
Patients were explained about the 
investigational nature of the study and 
informed written consent was taken before 
enrollment. Detail history and physical 
examination was done and advised for 
baseline routine investigations including 
fasting blood sugar, blood urea, serum 
creatinine, sodium, potassium, liver enzymes, 
SUA, calcium, phosphorus, total protein, 
albumin, urine routine examination and 
ultrasound abdomen and pelvis both for 
confirmation of cause of CKD and 
hyperuricemia and exclusion of patients with 
exclusion criteria.  
 
Predesigned pro-forma was used for data 
collection. Patient’s age, gender, serum 
creatinine, uric acid and liver enzymes (AST) 
were recorded. Patients with SUA >7mg/dl 
was prescribed Febuxostat 40 mg once a day 
at bed time and explained about the 
possibility of adverse effects like skin rashes, 
epigastralgia, vomiting, myopathy, joint pain 
and hepatotoxicity that will be diagnosed by 
liver enzyme estimation on follow up. All 
patients were followed up after 1, 2 and 3 
months with investigation reports of serum 
creatinine, uric acid and AST and adverse 
effects were inquired and recorded. The dose 
of Febuxostat was increased to 80 mg per day 
with persistent hyperuricemia of >8 mg/dl on 
follow up after one month. 
 
The eGFR was calculated by using abbreviated 
MDRD (modification of diet in renal disease) 
equation 186 × (creatinine/88.4) - 1.154 × 
(age) –0.203 × (0.742 if female) × (1.210 if 
black) 11 and CKD staging was done as per 
KDIGO guideline.12 
 
The data were entered in SPSS data sheet and 
inferential statistics was obtained by using 
SPSS software package. Data for continuous 
variables were expressed as mean ± standard 
deviation. Paired t-test was used to compare 
the mean difference before and after 
treatment and independent t test to compare 
uric acid level between patients with 40 mg 
and 80 mg of Febuxostat dose. Pearson 
correlation was used to see the relation 
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Total fifty CKD patients with eGFR < 60 
ml/min/1.73m2 and not on dialysis were 
studied. The causes of CKD were hypertensive 
nephrosclerosis (n=19), chronic 
glomerulonephritis (n=18), diabetic 
nephropathy (n=7), obstructive uropathy 
(n=4), chronic interstitial nephropathy (n=1) 
and autosomal dominant polycystic kidney 
disease (n=1).  
 
The mean age (years) of patients was 
54.2±16.5 (range 15-84) and 31 (68%) were 
male. The number of patients in CKD stage 3, 
4 and 5 ND were 24 (48%), 16 (32%) and 10 
(20%) respectively.   
 
Twelve (24%) patients with SUA > 8 mg/dl 
were prescribed Febuxostat 80 mg per day on 
follow up at one month and continued till the 
end of study. 
 
Febuxostat therapy had significantly and 
steadily decreased SUA (p=0.000) from 
baseline at one month, two month and three 
months. The SUA also decreased significantly 
in all CKD stages, Table 1. 
 
Reduction of SUA to <7 mg/dl was achieved in 
(44%, 82% and 94%) and <6 mg/dl in (10%, 
44% and 82%) at one, two and three months 
respectively, Figure 1 and SUA <6 mg/dl at 
three month was found in 87.5% of CKD stage 
3, 62.5% of CKD stage 4 and 100% of CKD 
stage 5.  
 
There was significant difference of mean uric 
acid level between patients with Febuxostat 
40 mg and 80 per day at baseline (8.5 ±1.2 vs 
10.1±1.3 p =0.000), one month (6.6 ±0.7 vs 
8.8±0.6, p=0.000), two month (5.6 ±0.7 vs 7.0 
±05, p=0.000) and three month (4.4 ±0.5 vs 
5.9±1.2, p=0.001) respectively. 
 
Febuxostat therapy had increased calculated 
eGFR (p=0.000) from baseline at one month, 
two month and three months, Figure 2. But 
on evaluating the eGFR in CKD stages, the 
significant increase of eGFR was present only 
in CKD stage 3 and stage 4 with insignificant 
improvement in CKD stage 5ND from baseline 
value at 1, 2 and 3 months as shown in Table 
2. By the end of 3 months therapy, 6 (25%) of 
CKD stage 3, 4 (25%) of CKD stage 4 and 2 
(20%) of CKD stage 5 had improved to CKD 
stage 2, CKD stage 3 and CKD stage 4 
respectively, Table 3.  
 
The Pearson correlation between uric acid 
and eGFR at baseline and follow up had 
shown insignificant negative correlation. 
 
The reported adverse effects were 
epigastralgia in 5 (10%) patients at 1 month 
and joint pain in 6 (12%) and 7 (14%) patients 
at 1 month and 2 months respectively. Liver 
enzymes were normal in all patients (19.0 
±3.0 vs 18.2±6.1 vs 19.1±5.1 vs 19.6±4.3) at 
baseline and follow up at one, two and three 
months respectively. 
 
Table 1. Baseline and follow up serum uric acid after Febuxostat treatment in hyperuricemic pre-dialysis 
chronic kidney disease patients (N=50) 
 
 Total  
(N=50) 
CKD Stage 3 
(N=24) 
CKD stage 4  
(N=16) 
CKD stage 5 
(N=10) 
Baseline 8.9±1.4 8.7±1.1 9.5±1.7 8.6±1.4 
1 month 7.1 ±1.2 6.9 ±1.0 7.48 ±1.16 7.1±1.4 
2 months 5.9 ±0.9 5.6 ±0.9 6.37 ± 0.8 6.0± 0 .8 
3 months 4.7 ±1.0 4.4 ±0.9 5.2 ±1.2 4.7± 0.4 
p value* 0.000! ~,# 0.000!, ~,# 0.001!  0.000~,# 0.004! 0.000~,# 
Final SUA < 6  41 (82%) 21 (87.5%) 10 (62.5%) 10 (100%) 
>6 9 (18%) 3 (12.5%) 6 (37.5%) 0 (0%) 
CKD: (Chronic Kidney Disease)  






Dineshowri Shrestha: Febuxostat in hyperuricemic CKD 
Journal of Patan Academy of Health Sciences. 2020Aug;7(2):45-52. 
Table 2. Serum Creatinine and eGFR of patients at baseline and follow-up 
 
 









1.7±0.3 1.6±0.3 1.6±0.3 1.5±0.3 0.000! , ~, # 
Stage 4 
(n=16) 
3.0±0.6 2.8±0.5 2.6±0.4 2.6±0.5 0.033!, 0.000~, # 
Stage 5 
(n=10) 





29.6±15.0 31.6±16.0 33.6±16.6 34.1±17.1 0.000! , ~, # 
Stage 3 
(n=24) 
42.7±8.9 45.3±9.0 47.5 ± 11.1 48.7±11.1 0.000! , ~, # 
Stage 4 
(n=16) 
22.0±4.3 23.6±0.5 25.9±5.2 25.6±5.3 0.023!, 0.000~, # 
Stage 5 
(n=10) 
10.2±2.5 11.4±4.9 12.6±5.3 12.7±5.8 NS! , ~, # 
⃰Paired t test, !baseline versus 1 month, ~baseline versus 2 month and #baseline versus 3 month, NS= Not significant 
 
 





CKD stage at three months of Febuxostat treatment 
Stage 2 
N (%) 
Stage 3  
N (%) 
Stage 4  
N (%) 
Stage 5  
N (%) 
Stage 3 (N=24) 6 (25%) 18 (75%) 0 0 
Stage 4 (N=16) 0 4 (25%) 12 (75%) 0 
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Our study demonstrated that SUA lowering 
effect of Febuxostat in hyperuricemic pre-
dialysis CKD is effective in all CKD stages. The 
significant reduction was observed at one 
month of therapy itself and continued till 3 
months, the end of study. Febuxostat is a 
novel and potent nonpurine-selective 
inhibitor of xanthine oxidase metabolized in 
the liver, is safe for patients with low eGFR 
without dose modification.13 Similar results of 
Febuxostat were also reported in a 
randomized controlled trial in Japan in 
patients with CKD stage 3.14 It was also 
reported in a retrospective analysis of CKD 
stage 4 and 5 (ND and on dialysis) in Taiwan 
on comparing SUA before and after 12 weeks 
treatment with Febuxostat.15 A meta-analysis 
has shown the beneficial effect of Febuxostat 
compared to control (placebo or allopurinol) 
from one month to six months, but no 
difference on 12th month of therapy.16 
 
Although hyperuricemia is defined as SUA >7 
mg/dl12, the target SUA level had been <6 
mg/dl in order to decrease gouty attack by 
inhibiting formation of new monosodium 
urate crystals and promoting dissolution of 
existing crystals in the joints and soft tissues.17 
The 2016 European League Against 
Rheumatism (EULAR) had recommended the 
target of urate lowering treatment should be 
to achieve SUA <6 mg/dl in all gouty 
patients.18 However, the efficacy of 
Febuxostat in lowering SUA in asymptomatic 
hyperuricemia in CKD was also evaluated with 
same target value. Efficacy of Febuxostat 
therapy have been reported in 58.1% patients 
with advanced CKD15, in 76.4% patient on 
chronic hemodialysis19 and in 82% patients 
with CKD stage 3b-5 at 12th week20. We found 
higher efficacy in82% of patients who 
achieved SUA <6mg/dl by the end of study 
period of 3 months. On further analyzing, it 
was found that in 87.5% of CKD stage 3, 62.5% 
of CKD stage 4 and 100% of CKD stage 5, 
indicating Febuxostat is an effective SUA 
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irrespective of degree of renal impairment. 
However, efficacy of drug could be dose 
dependent. In present study, daily dose was 
increased to 80 mg in 24% patients who had 
persistent SUA >8 mg/dl after one month of 
initial daily dose of 40mg therapy. The mean 
SUA was always significantly higher in patients 
with higher dosage justifying the treatment 
Out of 82% patients with SUA <6 mg/dl, 74% 
of patients were receiving 40 mg daily 
showing its efficacy even in low dose. 
 
Hyperuricemia is an independent risk factor 
for development and progression of CKD and 
AKI.21,22 Modest hyperuricemia in 
experimental rat models have shown 
exacerbated renal progression with higher BP, 
greater proteinuria and severe 
glomerulosclerosis, interstitial fibrosis and 
arteriolosclerosis.3 Population based studies 
have also shown renal impairment in people 
with normal renal function and baseline 
hyperuricemia on follow up.23,24 Treatment 
with uric acid lowering drugs (allopurinol, 
Febuxostat and probenecid) in CKD have 
shown to decrease the risk of renal failure 
events by 55% compared to standard 
treatment or placebo.25  Febuxostat has 
shown to maintain significantly higher mean 
eGFR values consistently for 4 years 
compared to allopurinol and control in 
patients with CKD stage 3.10 But, no difference 
of eGFR after 12 weeks therapy in CKD stage 4 
and 5.15 
 
In our study, we found significant 
improvement of eGFR after one month and it 
continued till the end of study period. 
However, subgroup analysis had shown the 
significant increment of eGFR only in CKD 
stage 3 and 4 and insignificant increment in 
CKD stage 5. In a meta-analysis, Lin TC et al 
have shown similar results with improvement 
of eGFR with Febuxostat only in subgroup 
analysis of patients with CKD stage 3 and 4 
and no improvement when compared with 
control.26 No difference in eGFR slope per 
year between Febuxostat and placebo 
therapy in CKD was reported in a randomized 
controlled trial.14 However, there are also 
reports showing improvement of eGFR with 
Febuxostat in CKD and significantly low 
prevalence of >10% decline of eGFR over 6 
months than placebo.27 After three months of 
Febuxostat treatment, the improvement of 
eGFR in our patients translated in to 
increment of CKD stage from baseline in 25% 
of CKD stage 3 and 4 and 20% of CKD stage 5 
supporting that significant reduction of SUA in 
hyperuricemic CKD is reno-protective and 
associated with significant improvement of 
eGFR. Studies have shown the linear inverse 
relationship of SUA with eGFR in patients with 
rheumatoid arthritis and in patients with CKD 
after allopurinol therapy.28,8 However, SUA 
and eGFR in our patients showed no 
significant negative correlation both at 
baseline and follow up. 
 
The Confirmation of Febuxostat in Reducing 
and Maintaining Serum Urate (CONFIRMS) 
trial have demonstrated the side effects of 
Febuxostat in patients with CKD were 
diarrhea, upper respiratory tract infection, 
rash and mildly raised liver enzymes and 
similar to patients without CKD.29However, 
Febuxostat treated patients had higher rates 
of acute gout flares than those treated with 
allopurinol which could be due to the rapid 
reduction in SUA with increased uric acid 
deposits.30 In present study, the adverse 
effects were joint pain in 26% and 
epigastralgia in 10%. The joint pains were not 
gouty arthritis.  All patients were treated 
conservatively and none were excluded from 
study due to adverse effects. 
 
Some of the limitations of this study is short 
duration, single center and no comparative 
group. However, based on our findings 
Febuxostat treatment seems effective in all 
pre-dialysis CKD patients with further 
multicenter, randomized controlled trial in 
CKD patients may answer some of the 





Our study found that Febuxostat therapy in 
hyperuricemic pre-dialysis CKD is beneficial 
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of CKD and improvement of eGFR in CKD 
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